ADDvise Group (ADDV) investor relations material

Executive summary

• Q2 organic sales grew 3.8% adjusted for FX, driven by lab equipment and clinical study rentals; EBITA margin improved to 15.5%, with EBITA nearly flat year-over-year.

• Cash flow from operations increased significantly, reflecting improved financial discipline.

• Macroeconomic and geopolitical uncertainty persists, with some softness in large CapEx sales cycles.

• New capital structure reduces annual interest expenses by SEK 56 million, supporting future growth.

• Focus remains on acquisition strategy and sustainable value creation.

Financial highlights

• Q2 net sales were SEK 396 million, up 4% year-over-year adjusted for FX, down 4% including FX.

• EBITA for Q2 was SEK 61 million, in line with last year, with a margin of 16%.

• Cash flow from operations was SEK 70 million, up from minus SEK 19 million last year.

• Pro forma net profit would be SEK 23 million versus reported SEK 10.8 million, reflecting new financing structure.

• Orders received in Q2 fell 24% year-over-year, impacted by a large prior-year order in the Lab unit.

Outlook and guidance

• Order book, adjusted for FX and last year’s large orders, is flat to slightly positive, indicating continued growth.

• Achieving 15% EBITDA growth for the year will require acquisitions; standalone growth will be challenging.

• Updated long-term targets: average annual EBITA growth of 15%, ROCE of 15%, net debt/EBITDA not to exceed 3.0x, and up to 25% of prior year profit as dividend.